Skip to main content

Serum sodium as a potential biomarker for immunotherapy response in metastatic RCC-real-world evidence from a German multicentre cohort.

Clinical & translational immunology

Authors: Alix Tschirhart, Alexander Cox, Benedikt Hoeh, Cristina Cano Garcia, Angelika Mattigk, Marcus Sondermann, Thomas Büttner, Marcel Schwinger, Jonathan Vollemaere, Kati Erdmann, Philipp Schmucker, Luka Flegar, Friedemann Zengerling, Severine Banek, Johannes Huber, Philip Zeuschner, Charis Kalogirou, Niklas Klümper, Jonas Saal

OBJECTIVES: Sodium is increasingly recognised as a modulator of immune function, and higher baseline serum sodium has been linked to improved outcomes with immune checkpoint inhibitor (IO)-based therapy in post hoc analyses of randomised trials. We aimed to validate the prognostic relevance of baseline serum sodium in patients with metastatic renal cell carcinoma (mRCC) treated with currently approved IO-based combinations in real-world clinical practice.

METHODS: We analysed 256 patients from a German multicentre real-world cohort with mRCC who received first-line nivolumab plus ipilimumab (IO + IO,  = 75) or an IO plus tyrosine kinase inhibitor combination (IO + TKI,  = 181) and had baseline serum sodium available. Overall survival (OS) and progression-free survival (PFS) were assessed by baseline serum sodium category (< 135, 135-140, > 140 mmol/L) using Cox regression and Kaplan-Meier analysis, both overall and stratified by treatment.

RESULTS: Higher baseline serum sodium (≥ 135 mmol/L) was significantly associated with improved OS in the overall cohort. This association was confined to patients treated with IO + IO, in whom higher sodium was linked to both improved OS and PFS; no significant associations were observed with IO + TKI.

CONCLUSIONS: Baseline serum sodium is a readily available prognostic biomarker in mRCC, particularly in patients treated with dual immune checkpoint blockade, and warrants prospective validation.

PATIENT SUMMARY: In patients with advanced kidney cancer treated with immunotherapy, normal or enhanced blood sodium levels were linked to longer survival. This effect was mainly seen in patients receiving intensified immunotherapy. Measuring sodium may help identify patients who benefit most from certain treatments.

TAKE‐HOME MESSAGE: Higher baseline serum sodium is associated with improved survival in metastatic renal cell carcinoma treated with dual immune checkpoint blockade. Sodium may represent a simple, low-cost biomarker to support treatment selection in contemporary immunotherapy regimens.

© 2026 The Author(s). Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.

PMID: 43060739

Participating cluster members